Table 4 The efficacy of each drug, evaluated by using the neurological symptoms of neuropathic pain related to spinal disorders.

From: Symptom-based pharmacotherapy for neuropathic pain related to spinal disorders: results from a patient-based assessment

 

Drug

p

Pregabalin

Mirogabalin

Duloxetine

Neurotropin

Number of patients

109

63

54

39

 

Spinal cord-related pain

Base-line NPSI

16.1±9.1

18.2±11.4

17.2±9.0

18.3±13.1

0.99

Follow-up NPSI

12.4±9.4

13.1±9.3

14.4±9.8

15.7±7.9

0.81

30% Responder, n (%)

16/40 (40.0)

11/24 (45.8)

7/15 (46.7)

2/8 (25.0)

0.74

50% Responder, n (%)

7/40 (17.5)

7/24 (29.2)

0/15 (0)

0/8 (0)

0.055

Radicular pain

Baseline NPSI

14.9±10.2

13.0±7.7

15.0±10.5

11.6±6.4

0.77

Follow-up NPSI

8.6±7.8

8.1±5.0

10.1±6.8

7.2±5.4

0.64

30% Responder, n (%)

32/45 (71.1)

15/20 (75.0)

7/15 (46.7)

12/16 (75.0)

0.27

50% Responder, n (%)

15/45 (33.3)

7/20 (35.0)

5/15 (33.3)

7/16 (43.8)

0.89

Cauda equina syndrome

Baseline NPSI

15.6±11.4

16.6±10.1

17.7±10.3

12.7±5.5

0.68

Follow-up NPSI

11.5±8.2

11.3±8.1

11.8±8.3

6.5±3.8

0.30

30% Responder, n (%)

13/24 (54.2)

12/19 (63.2)

15/24 (62.5)

12/15 (80.0)

0.47

50% Responder, n (%)

6/24 (25.0)

7/19 (36.8)

11/24 (45.8)

7/15 (46.7)

0.41

  1. Data are shown as the mean ± the standard deviation. Bold, notable results.
  2. ⁑p<0.01, compared to total patients with radicular pain and cauda equina syndrome.
  3. NPSI Neuropathic Pain Symptom Inventory.
Back to article page